vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and MVB FINANCIAL CORP (MVBF). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $36.7M, roughly 2.0× MVB FINANCIAL CORP). MVB FINANCIAL CORP runs the higher net margin — 0.0% vs -121.9%, a 121.9% gap on every dollar of revenue. Over the past eight quarters, MVB FINANCIAL CORP's revenue compounded faster (2.8% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

MVB Financial Corp is a U.S.-based financial holding company offering commercial and retail banking services, wealth management, mortgage lending, and deposit products. It also provides specialized digital banking solutions for fintech and gaming enterprises, primarily serving customers across the U.S. Mid-Atlantic region.

HCAT vs MVBF — Head-to-Head

Bigger by revenue
HCAT
HCAT
2.0× larger
HCAT
$74.7M
$36.7M
MVBF
Higher net margin
MVBF
MVBF
121.9% more per $
MVBF
0.0%
-121.9%
HCAT
Faster 2-yr revenue CAGR
MVBF
MVBF
Annualised
MVBF
2.8%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HCAT
HCAT
MVBF
MVBF
Revenue
$74.7M
$36.7M
Net Profit
$-91.0M
$0
Gross Margin
Operating Margin
-115.3%
Net Margin
-121.9%
0.0%
Revenue YoY
-6.2%
Net Profit YoY
-340.3%
EPS (diluted)
$-1.29
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
MVBF
MVBF
Q1 26
$36.7M
Q4 25
$74.7M
$39.1M
Q3 25
$76.3M
$61.2M
Q2 25
$80.7M
$33.7M
Q1 25
$79.4M
$33.7M
Q4 24
$79.6M
$46.2M
Q3 24
$76.4M
$33.2M
Q2 24
$75.9M
$34.7M
Net Profit
HCAT
HCAT
MVBF
MVBF
Q1 26
$0
Q4 25
$-91.0M
$4.2M
Q3 25
$-22.2M
$17.1M
Q2 25
$-41.0M
$2.0M
Q1 25
$-23.7M
$3.6M
Q4 24
$-20.7M
$9.4M
Q3 24
$-14.7M
$2.1M
Q2 24
$-13.5M
$4.1M
Gross Margin
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Operating Margin
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
-115.3%
13.9%
Q3 25
-22.9%
38.3%
Q2 25
-46.0%
9.4%
Q1 25
-25.4%
14.3%
Q4 24
-22.0%
26.5%
Q3 24
-17.9%
8.4%
Q2 24
-20.8%
15.9%
Net Margin
HCAT
HCAT
MVBF
MVBF
Q1 26
0.0%
Q4 25
-121.9%
10.8%
Q3 25
-29.1%
28.0%
Q2 25
-50.8%
5.9%
Q1 25
-29.9%
10.6%
Q4 24
-26.0%
20.4%
Q3 24
-19.3%
6.3%
Q2 24
-17.8%
11.8%
EPS (diluted)
HCAT
HCAT
MVBF
MVBF
Q1 26
$0.39
Q4 25
$-1.29
$0.32
Q3 25
$-0.32
$1.32
Q2 25
$-0.59
$0.15
Q1 25
$-0.35
$0.27
Q4 24
$-0.33
$0.72
Q3 24
$-0.24
$0.16
Q2 24
$-0.23
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
MVBF
MVBF
Cash + ST InvestmentsLiquidity on hand
$95.7M
$177.6M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$334.9M
Total Assets
$502.6M
$3.3B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
MVBF
MVBF
Q1 26
$177.6M
Q4 25
$95.7M
$244.1M
Q3 25
$91.5M
$300.0M
Q2 25
$97.3M
$399.4M
Q1 25
$342.0M
$251.4M
Q4 24
$392.0M
$317.9M
Q3 24
$387.3M
$610.9M
Q2 24
$308.3M
$455.5M
Total Debt
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Stockholders' Equity
HCAT
HCAT
MVBF
MVBF
Q1 26
$334.9M
Q4 25
$245.8M
$334.0M
Q3 25
$331.9M
$327.8M
Q2 25
$347.5M
$302.3M
Q1 25
$376.8M
$310.1M
Q4 24
$365.2M
$305.7M
Q3 24
$355.0M
$303.1M
Q2 24
$357.0M
$296.6M
Total Assets
HCAT
HCAT
MVBF
MVBF
Q1 26
$3.3B
Q4 25
$502.6M
$3.3B
Q3 25
$587.1M
$3.2B
Q2 25
$616.2M
$3.2B
Q1 25
$891.5M
$3.0B
Q4 24
$858.9M
$3.1B
Q3 24
$813.0M
$3.4B
Q2 24
$691.7M
$3.3B
Debt / Equity
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
MVBF
MVBF
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
$9.9M
$4.0M
Q3 25
$-464.0K
$-2.6M
Q2 25
$-9.0M
$7.4M
Q1 25
$280.0K
$14.1M
Q4 24
$-3.5M
$-285.0K
Q3 24
$6.2M
$8.6M
Q2 24
$1.6M
$26.9M
Free Cash Flow
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
$9.6M
$2.1M
Q3 25
$-719.0K
$-3.5M
Q2 25
$-9.2M
$7.2M
Q1 25
$-390.0K
$13.9M
Q4 24
$-3.9M
$-1.9M
Q3 24
$5.5M
$8.3M
Q2 24
$1.3M
$26.6M
FCF Margin
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
12.9%
5.4%
Q3 25
-0.9%
-5.8%
Q2 25
-11.4%
21.5%
Q1 25
-0.5%
41.2%
Q4 24
-4.9%
-4.1%
Q3 24
7.2%
25.1%
Q2 24
1.7%
76.7%
Capex Intensity
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
0.4%
4.9%
Q3 25
0.3%
1.6%
Q2 25
0.3%
0.6%
Q1 25
0.8%
0.8%
Q4 24
0.5%
3.5%
Q3 24
0.9%
0.9%
Q2 24
0.4%
0.7%
Cash Conversion
HCAT
HCAT
MVBF
MVBF
Q1 26
Q4 25
0.95×
Q3 25
-0.15×
Q2 25
3.72×
Q1 25
3.95×
Q4 24
-0.03×
Q3 24
4.15×
Q2 24
6.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

MVBF
MVBF

Net Interest Income$28.5M78%
Noninterest Income$8.2M22%

Related Comparisons